Suppr超能文献

1 型糖尿病受者中行活体供肾与胰腺联合移植与单纯行活体供肾移植的比较。

Transplantation with pancreas after living donor kidney vs. living donor kidney alone in type 1 diabetes mellitus recipients.

机构信息

David Geffen School of Medicine at UCLA, Kidney and Pancreas Transplant Program, Los Angeles, CA, USA.

出版信息

Clin Transplant. 2010 Nov-Dec;24(6):812-20. doi: 10.1111/j.1399-0012.2009.01195.x.

Abstract

Living donor kidney transplantation (LDKT) in type 1 diabetic recipients (T1DM) may be followed by a pancreas after living donor kidney (PALK). The impact of the PALK is largely unknown. Adult T1DM living donor kidney recipients (1997-2007) listed for pancreas transplantation were divided into those who subsequently received pancreas transplantation and those who did not (living donor kidney transplant alone [LDKA]). Outcomes were compared. A sub-analysis was performed in recipients with at least one yr of kidney graft survival and limiting PALK to those who underwent pancreas transplantation in the first year. Of 4554 recipients, 23% received PALK. PALK had more favorable baseline characteristics. At the end of eight yr, we found significantly superior patient (85% vs. 75%) and kidney graft survival (75% vs. 62%) in PALK group. The adjusted hazard ratios of PALK (LDKA as reference) were 0.65 (95%CI: 0.52-0.81) for death and 0.63 (0.54-0.76) for renal graft loss. In sub-group analysis, there was a trend toward decreased death in PALK (HR = 0.78: 0.57-1.07). In conclusion, only 23% of those wait-listed received a pancreas with patient and kidney survival superior to LDKA. Pancreas transplant in the first year after kidney transplant was associated with a trend toward better long-term patient survival.

摘要

1 型糖尿病受者(T1DM)的活体供肾移植(LDKT)后可能会进行活体供肾胰腺移植(PALK)。PALK 的影响在很大程度上尚不清楚。1997-2007 年,接受活体供肾移植的成年 T1DM 受者(living donor kidney transplant alone [LDKA])按是否随后接受胰腺移植分为两组,比较两组的结局。在至少有 1 年的肾移植物存活的受者中进行了亚组分析,并将 PALK 限于在第 1 年接受胰腺移植的受者。在 4554 名受者中,23%接受了 PALK。PAKL 具有更有利的基线特征。在 8 年结束时,我们发现 PALK 组患者(85% vs. 75%)和肾移植物存活率(75% vs. 62%)显著更高。PAKL(以 LDKA 为参考)的调整后的危险比为 0.65(95%CI:0.52-0.81)的死亡和 0.63(0.54-0.76)的肾脏移植物丢失。在亚组分析中,PAKL 组的死亡风险呈下降趋势(HR = 0.78:0.57-1.07)。总之,只有 23%的等候名单上的患者接受了胰腺移植,患者和肾脏存活率优于 LDKA。在肾移植后第 1 年进行胰腺移植与长期患者存活率的提高呈趋势相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验